Friday, May 13, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

New COVID-19 vaccine promises vaccine equity because it has no patents

by Medical Finance
in Coronavirus
Researchers analyze the role of self-deception in everyday life
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Corbevax, a new vaccine against COVID-19, may have better success as a candidate for vaccine equity because it carries no patents, relies on long-established recombinant technology for manufacture and has the support of the US and Indian governments, its makers and health experts say.

The vaccine already has emergency use approval in India and the Hyderabad-based collaborator, Biological E Limited, is set to produce 100 million doses a month, starting February, according to a company spokesperson.

India’s Biotechnology Industry Research Assistance Council (BIRAC) helped see Corbevax through the pre-clinical stage and the Phase III clinical studies and is expected to advocate early clearances from the WHO.

Mahima Datla, managing director of Biological E, says once WHO clearances come through, Biological E is confident that it can scale up manufacturing to deliver 300 million doses as promised to the Indian government and an additional one billion doses globally.

Corbevax’s development owed mainly to a long-standing partnership to produce various vaccines between Biological E, the Texas Children’s Hospital Center for Vaccine Development, and the Baylor College of Medicine in Houston, Texas.

Over the years, we worked together to produce vaccines that were of good quality and accessible around the world. Given this background, we could readily develop Corbevax as an effective and affordable vaccine against COVID-19.”


Mahima Datla, Managing Director of Biological E

Srinath Reddy, president of the Public Health Foundation of India, tells SciDev.Net that “Corbevax is easy to manufacture and distribute because the recombinant technology used has been employed for decades to produce, for example, the Hepatitis-B vaccine”.

Unlike mRNA and several other vaccines which require extremely low cold chains, Corbevax can be stored and transported at 2—8 degree Celsius, allowing countries with limited resources to store and distribute it, Reddy said. It could prove ideal for booster doses for which trials are now being conducted in India, he added.

Biological E affirmed that the vaccine was found to be safe, well-tolerated and immunogenic [capable of building immunity] following the completion of phase III clinical trials involving more than 3,000 subjects between the ages of 18 and 80 at 33 sites across India.

Phase III studies showed Corbevax stimulating a better immune response than Covishield, a vaccine developed by Astra-Zeneca and the Oxford University, which is being manufactured in India and is the mainstay of the country’s COVID-19 immunisation programme. It also had fewer adverse reactions.

Reddy expects Corbevax to be cheaper than most existing vaccines mainly because of the intellectual property rights waiver announced by its main co-creator, Peter Hotez, co-director of the Texas Children’s Hospital Center for Vaccine Development and professor at the Baylor College of Medicine.

Hotez said in a tweet on 28 December: “We technology transferred our vaccine and helped in its co-development with Biological E with no patent and no strings attached. As a result, it should be the least expensive COVID vaccine available yet.”

“This vaccine can be made locally all over the world, and we’ve now technology transferred our Texas Children’s vaccine to producers in India, Indonesia, Bangladesh, Botswana. Our Texas Children’s Center does not plan to make money on this, it’s a gift to the world,” Hotez also tweeted.

On 17 January, addressing the World Economic forum in Geneva, UN Secretary-General Antonio Guterres said the world was “nowhere near the targets” set by the WHO to vaccinate 40 per cent of people in all countries by end 2021 and 70 per cent by the middle of this year.

“Vaccination rates in high-income countries are – shamefully – seven times higher than in African countries,” Guterres said. “We need vaccine equity, now. We need pharmaceutical companies to stand in solidarity with developing countries by sharing licenses, knowhow and technology so we can all find a way out of this pandemic.”

Reddy said the world cannot wait any longer for developed countries to share licenses and resolve rivalries over patents. “It is far better to use time-tested and safety-proven technology — like that used for the creation of Corbevax — to immunise as many people as possible in the shortest possible time.”

Corbevax, said Reddy, would be particularly useful for the global vaccination programme in the face of emerging COVID-19 variants such as Omicron, now sweeping across many countries, including India.

“We believe that this vaccine will address the needs of the world and help the global population fighting against the spread of COVID-19,” the Ministry of Health and Family Welfare said in a statement.

Emergency use approval for Corbevax was granted in India on 28 December along with similar approval for Covovax, a subunit vaccine developed by the US-based Novovax, licensed to be manufactured by the Serum Institute of India.

Two other US vaccines already deployed in India are Moderna, which uses the genetic code of messenger RNA (mRNA) to prime the immune system to respond to COVID-19, and Johnson and Johnson, a single-dose adenovirus vector vaccine. Adenoviruses are common viruses that cause cold- or flu-like illness while vectors are inactivated viruses that can stimulate the immune system to generate antibodies.

A DNA vaccine produced by the Ahmedabad-based Zydus Cadila called ZyCoV-D does not need syringes but is administered with a needle-free applicator. DNA vaccines work by transferring a genetically modified blueprint of viral genes into small molecules of DNA or genetic material for injection.

With such an array of COVID-19 vaccines, India has already covered 90 per cent of its eligible population with a first dose and 65 per cent with a second dose.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Researchers analyze the role of self-deception in everyday life

Researchers analyze the role of self-deception in everyday life

by Medical Finance
May 13, 2022
0

A philosophy team from Ruhr-Universität Bochum (RUB) and the University of Antwerp analyzed the role self-deception plays in everyday life...

Study: Evidence of early community transmission of Omicron (B1.1.529) in Delhi- A city with very high seropositivity and past exposure! Image Credit: REC Stock Footage / Shutterstock.com

Indian study suggests significant decrease in protection from vaccine or natural immunity against Omicron variant

by Medical Finance
May 13, 2022
0

In a recent study published on the medRxiv* preprint server, researchers present evidence for early community transmission of the severe...

Study: Immune Response To SARS-Cov-2 In Severe And Long COVID-19. Image Credit: Cristian Moga/Shutterstock

Mathematical model of host immune response to SARS-CoV-2 demonstrates that age-related risk factors increased viral load

by Medical Finance
May 13, 2022
0

In a recent study posted to the Research Square* preprint server and under consideration at Scientific Reports, researchers evaluated the host...

Study: SARS-CoV-2 Suppression and Early Closure of Bars and Restaurants: A Longitudinal Natural Experiment. Image Credit: Wirestock Creators/Shutterstock

Closing bars and restaurants does not appear to have suppressed COVID-19 in Japan

by Medical Finance
May 13, 2022
0

In a recent study posted in the Research Square* preprint server, which is under consideration at the journal Scientific Reports, a...

Study: White Blood Cell Variability and Clinical Outcomes in Hospitalized Patients With COVID-19. Image Credit: cenksns/Shutterstock

White blood cell count as a prognostic indicator of COVID-19

by Medical Finance
May 13, 2022
0

In a recent study posted to Research Square* preprint server, and currently under consideration at the Journal of Inflammation, researchers...

Study: Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination. Image Credit: mailsonpignata/Shutterstock

Declining immune responses against SARS-CoV-2 variants in dialysis patients post-vaccination

by Medical Finance
May 13, 2022
0

To prevent infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or at minimum provide protection against severe complications associated...

Next Post
Study: SARS-CoV-2 and Arthropods: A Review. Image Credit: InsectWorld/Shutterstock

The potential for SARS-CoV-2 to be transmitted biologically or mechanically by arthropods

Study: Long Covid: A Systematic Review and Meta-Analysis of 120,970 Patients. Image Credit: Starocean/Shutterstock

Systematic review with meta-analysis of the current evidence regarding the incidence of long COVID symptomatology

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • demand for us travel nurses plunges
    Travel nurses see swift change of fortunes as covid money runs dry
  • nanoparticles 620x480
    Genome editing in vascular endothelial cells made possible with a powerful new delivery system
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply